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Objective: Several lines of evidence suggest that estrogens inﬂuence the development of osteoarthritis
(OA). The aim of this study was to explore the association of two common polymorphisms within the
aromatase (CYP19A1) and estrogen receptor (ER) alpha (ESR1) genes with severe OA of the lower limbs.
Methods: The rs1062033 (CYP19A1) and rs2234693 (ESR1) single nucleotide polymorphisms were
genotyped in 5528 individuals (3147 patients with severe hip or knee OA, and 2381 controls) from four
centres in Spain and the United Kingdom. Gene expression was measured in femoral bone samples from
a group of patients.
Results: In the global analysis, both polymorphisms were associated with OA, but there was a signiﬁcant
sex interaction. The GG genotype at rs1062033 was associated with an increased risk of knee OA in
women [odds ratio (OR) 1.23; P¼ 0.04]. The CC genotype at rs2234693 tended to be associated with
reduced OA risk in women (OR 0.76, P¼ 0.028, for knee OA; OR¼ 0.84, P¼ 0.076 for hip OA), but with
increased risk of hip OA in men (OR 1.28; P¼ 0.029). Women with unfavourable genotypes at both loci
had an OR of 1.61 for knee OA (P¼ 0.006). The rs1062033 genotype associated with higher OA risk was
also associated with reduced expression of the aromatase gene in bone.
Conclusions: Common genetic variations of the aromatase and ER genes are associated with the risk of
severe OA of the large joints of the lower limb in a sex-speciﬁc manner. These results are consistent with
the hypothesis that estrogen activity may inﬂuence the development of large-joint OA.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a prevalent disorder that frequently
impairs the quality of life in middle aged and elderly individuals
and represents a considerable economical burden to health-care
systems. Among individuals over 45 years of age, several studies
have reported a prevalence of hip OA of between 7 and 27%, and of
approximately 16% for knee OA1. Joint replacement surgery, mostly
at the hip and the knee, represents a major component of the
activity of orthopaedic surgery departments, with the number of.A. Riancho, Departamento de
d de Cantabria, Av Valdecilla
s Research Society International. Poperations expected to increase six-fold by the year 20302. There-
fore, a better understanding of the pathophysiology of OA is
important to establish effective preventive strategies. OA is
currently seen as a complex disorder resulting from the interaction
between acquired and genetic factors. The heritability of OA at
different sites has been estimated to be approximately 75% at the
spine, 65% at the hand, 60% at the hip, and 40% at the knee, with
some suggestions for a more important contribution of heredity in
females than in males3,4. Although the damage to the cartilage is
frequently emphasized in OA, there is evidence suggesting that
changes to the synovium and the subchondral bone are also
involved in the OA disease process5.
Estrogens are critical modulators of bone homeostasis, in
females and in males6. They have also been shown to modulate
chondrocyte activity and the synthesis of a variety of factors,
including metalloproteinases, nitric oxide and reactive oxygenublished by Elsevier Ltd. All rights reserved.
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matrix7e10. Estrogens act through the binding to two types of
speciﬁc estrogen receptors (ERs), encoded by different genes: a (or
ESR1) and b (or ESR2). ESR1 seems to have a more consistent role in
both sexes6. ERs are expressed by a variety of cells in the skeleton,
including stromal cells, osteoblasts and chondrocytes11. ER genes
have been considered as appealing candidates potentially contrib-
uting to the genetic component of OA, but conﬂicting results have
so been reported [recently reviewed by Ryder et al.12]. However,
various studies suggest that estrogens may indeed inﬂuence the
development of OA13; low levels of estrogens have been associated
with an increased risk of OA in some studies14, whilst estrogen
replacement therapy may have a protective role on the develop-
ment of OA, both in experimental animals and in humans15e18. In
fact, increased osteophytosis has been reported in ER knock-out
mice19. However, the protective effect of estrogens has not been
demonstrated in all studies, and conﬂicting results have been
reported in primate models of OA17,20,21.
In postmenopausal women and in men, the aromatization of
androgenic precursors in peripheral tissues is the main source
of estrogens. The reaction is catalyzed by aromatase, the product of
the CYP19A1 gene, located on chromosome 15 (15q21.1). The
synthesis of estrogens by aromatase-expressing bone cells may
have important effects at the skeletal tissue level, independent of
the circulating levels of estrogens. In fact, we have recently shown
that aromatase expression is reduced in the bone tissue of patients
with severe hip OA, in comparison to patients with hip fractures22.
Therefore, we hypothesized that allelic variants of genes inﬂu-
encing estrogen synthesis and/or response could inﬂuence the risk
of OA. The objective of this study was to explore the association of
two common polymorphisms of the aromatase and ERa genes with
primary OA of the lower limb.Methods
Subjects
We studied 5528 individuals aged 55 years and older (2176
patients with hip OA, 971 patients with knee OA and 2381 controls)
recruited at three centres in Spain (Santander, Santiago and
Coruña) and one centre in the United Kingdom, Oxford (Table I).
The Spanish cohorts included Caucasian individuals of Spanish
ancestry living in two regions in Northern Spain (Cantabria,
Santander cohort; or Galicia, Santiago and Coruña cohorts). The
Oxford cohort comprised individuals of Caucasian ethnicity from
Oxford and from other parts of the UK. Patients had severe,
radiographically conﬁrmed, primary OA requiring hip or knee joint
replacement surgery. Exclusion criteria included individuals with
secondary OA (due to systemic diseases, rheumatoid arthritis,
infections, trauma, ischemic necrosis, neurological diseases, etc.),
whowere excluded by clinical, laboratory and radiographic studies.
The control group included volunteers recruited by voice andTable I
Characteristics of study subjects
Santander Coruña Santiago Oxford
Individuals (n) 1433 496 1014 2585
Controls (n) 802 244 473 862
Hip OA (n) 359 252 287 1278
Knee OA (n) 272 e 254 445
Age (mean, SD)
Controls 71 10 65 13 68 9 69 7
Hip OA 71 7 67 14 68 5 65 6
Knee OA 72 7 e 68 6 64 5
Sex (% women) 61 62 55 56written announcements, patient’s spouses, and individuals taking
part in a cohort study of osteoporosis risk factors. They had no
clinically evident OA at the lower extremities, but X-rays were not
obtained routinely in the absence of a clinical justiﬁcation. The
study was approved by local ethics committees and all individuals
gave informed written consent.Genotyping
DNA was extracted from the peripheral blood or buccal swabs
using standard procedures. Two single nucleotide
polymorphisms (SNPs) were genotyped; the rs1062033 SNP
located in the 50 untranslated region (50UTR) of the aromatase gene
CYP19A1 and the rs2234693 SNP located in intron 1 of the ERa gene
ESR1. rs1062033 has been shown to be associated with differences
in gene transcription at CYP19A1 and with BMD in postmenopausal
women23,24, whilst rs2234693 has been suggested to inﬂuence OA
risk in some studies25e27. In the Santander and Oxford cohorts the
SNPs were genotyped by TaqMan allelic discrimination assays
(Applied Biosystems, Foster City, CA, USA), as previously
described23. In the Santiago and Coruña cohorts they were geno-
typed by a single-base extension procedure, involving a multiplex
polymerase chain reaction (PCR) (Qiagen Multiplex PCR, Valencia,
CA, USA; oligonucleotide primer sequences and PCR conditions are
available upon request) followed by single-base extension reactions
performed with the SNaPshot Multiplex Kit (Applied Biosystems).
In each laboratory, 5% samples were analyzed at least twice in
different days to conﬁrm the genotyping reproducibility. Twelve
samples were genotyped in different laboratories to check the
consistency of results with both genotyping methods. Alleles were
designated according to the human reference sequences (minus
strand for the CYP19A1 gene, plus strand for the ESR1 gene; Genome
build 36.3).Gene expression
CYP19A1 and ESR1 expression was studied by real-time quanti-
tative PCR, as previously described22. Biopsy sampleswere obtained
from the femoral head removed during joint replacement for hip
OA. Small fragments of trabecular bone were extensively washed
with PBS, snap-frozen in liquid nitrogen and stored at 70C.
Unthawed fragments were ground to a powder using a tissue
homogenizer intoTrizol (Invitrogen) to extract RNA,whose integrity
was then monitored by gel electrophoresis and whose concentra-
tion was measured by absorptiometry. Aliquots of RNA (approxi-
mately 1 mg) were reverse transcribed with the Superscript III kit
(Invitrogen), using randomhexamers as primers. In negative control
reactions reverse transcriptase was omitted. After reverse tran-
scription, the expression of CYP19A1 and ESR1 was determined by
real-time PCR in an ABI7300 apparatus (Applied Biosystems). The
reactions were performed in triplicate in 96-well plates containing
aliquots of cDNA obtained by reverse transcription, 5 ml of universal
PCR master mix, and speciﬁc primers and probes for CYP19A1 and
ESR1 (TaqMan Gene Expression Assays, Applied Biosystems).
The cycle threshold (Ct) was determined. This represents the
cycle at which a signiﬁcant increase in ﬂuorescence is ﬁrst detected
and is inversely related to the amount of target cDNA in the starting
material. The results were normalized to TBP (TATA box binding
protein) expression analyzed in the same reaction plate. Control
samples of reverse transcribed reference human RNA (Stratagene,
La Jolla, CA) were also included. The relative RNA levels were
calculated using the formula 10 2DCt1DCt2, where DCt1 is the
difference between the control cDNA Ct and the sample cDNA Ct
when the target gene (CYP19A1, ESR1) is ampliﬁed, and DCt2 is the
Table II
Genotype and allele frequencies in males and females (percentages in parentheses)
Cohort Group rs1062033 rs2234693
CC/CG GG C G TT/CT CC T C
Males
Santander Control 182 (64) 103 (36) 0.36 0.64 229 (80) 56 (20) 0.55 0.45
Knee OA 58 (61) 37 (39) 0.36 0.64 79 (83) 16 (17) 0.58 0.42
Hip OA 109 (61) 71 (39) 0.35 0.65 133 (74) 47 (26) 0.50 0.50
Santiago Control 190 (64) 105 (36) 0.34 0.66 250 (85) 45 (15) 0.62 0.38
Knee OA 22 (47) 25 (53) 0.37 0.63 34 (72) 13 (28) 0.48 0.52
Hip OA 76 (69) 34 (31) 0.31 0.69 91 (83) 19 (17) 0.59 0.41
Coruña Control 67 (69) 30 (31) 0.46 0.54 79 (81) 18 (19) 0.56 0.44
Knee OA e e e e
Hip OA 63 (70) 27 (30) 0.46 0.54 72 (80) 18 (20) 0.59 0.41
Oxford Control 330 (70) 141 (30) 0.46 0.54 385 (82) 86 (18) 0.55 0.45
Knee OA 125 (71) 51 (29) 0.49 0.51 144 (82) 32 (18) 0.54 0.46
Hip OA 363 (72) 140 (28) 0.47 0.53 395 (79) 108 (21) 0.56 0.44
Females
Santander Control 358 (69) 159 (31) 0.43 0.57 394 (76) 123 (24) 0.52 0.48
Knee OA 107 (61) 70 (39) 0.40 0.60 140 (79) 37 (21) 0.53 0.47
Hip OA 114 (64) 65 (36) 0.40 0.60 146 (82) 33 (14) 0.57 0.43
Santiago Control 129 (73) 49 (27) 0.44 0.56 143 (80) 35 (20) 0.57 0.43
Knee OA 132 (64) 75 (36) 0.43 0.57 174 (84) 33 (16) 0.55 0.45
Hip OA 108 (61) 69 (39) 0.40 0.60 145 (82) 32 (18) 0.58 0.42
Coruña Control 95 (65) 52 (35) 0.40 0.60 116 (79) 31 (21) 0.55 0.45
Knee OA e e e e
Hip OA 116 (72) 46 (28) 0.48 0.52 130 (80) 32 (20) 0.57 0.43
Oxford Control 281 (72) 110 (28) 0.47 0.53 310 (79) 81 (21) 0.55 0.45
Knee OA 188 (70) 81 (30) 0.46 0.54 224 (83) 45 (17) 0.56 0.44
Hip OA 535 (69) 240 (31) 0.44 0.56 626 (81) 149 (19) 0.57 0.43
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the control gene (TBP) is ampliﬁed.
Data analysis
HardyeWeinberg equilibrium in controls was tested with
HWSIM software (http://krunch.med.yale.edu/hwsim/hwsim.doc).
Differences in genotype distribution in each cohort and in the
combined study population were analyzed with the c2 test and by
unconditional logistic regression analysis after genotype grouping.
As measures of association, the odds ratios (ORs) and their 95%
conﬁdence intervals (CIs) were calculated for each cohort. The
global OR combining all cohorts and the adjustedManteleHaenszel
OR (weighted by each stratum variance) were calculated as
summary estimates of effect. Assuming a minor allele frequency of
0.4, the study power to detect an effect size associated with an OR
of at least 1.4 was higher than 90%, in the global and the sex-Knee OA, CYP19A1 genotype
1
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426. 8.
OR
Fig. 1. Association of CYP19A1 SNP rs1062033 GG genotype and ESR1 SNP rs2234693 CC geno
CIs are shown.stratiﬁed analysis, under a log-additive model. The non-parametric
JonckheereeTerpstra test for ordered categories was used to
analyze the differences in gene expression between subjects with
different genotypes. SPSS (SPSS Inc, Chicago, IL, USA) and EPIDAT
software (http://dxsp.sergas.es/ApliEdatos/Epidat/cas/default.asp)
were used in the statistical analyses. Study power calculations were
done with QUANTO (http://hydra.usc.edu/gxe).
Results
Genetic variations and OA
In thewhole study group, the genotype frequencies were similar
to those reported in other Caucasian populations. The CYP19A1 SNP
rs1062033 genotypes were: CC 20%, CG 48%, and GG 32%. The ESR1
SNP rs2234693 genotype frequencies were: TT 30%, TC 50%, CC 20%.
There was no evidence for departure from the HardyeWeinbergKnee OA, ESR1 genotype
All
Oxford
Santiago
Santander
1 426. 8.
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type with knee OA in women. The individual ORs, the global combined OR and the 95%
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Fig. 2. Association of CYP19A1 SNP rs1062033 GG genotype and ESR1 SNP rs2234693 CC genotype with hip OA in women. The individual ORs, the global combined OR and the 95%
CIs are shown.
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unstratiﬁed data did not show signiﬁcant differences in genotype
distributions between cases and controls for either SNP. However,
in sex-adjusted logistic regression models the genotypes at both
SNPs were associated with OA (rs1062033, P¼ 0.023; rs2234693,
P¼ 0.03), and there was a signiﬁcant interaction between sex and
the genotypes (P¼ 0.04 for CYP19A1 and 0.006 for ESR1). Therefore,
all subsequent analyses were stratiﬁed by sex. A dominant model
for rs1062033 and a recessive model for rs2234693 best ﬁtted the
data. The genotype frequency distributions in the study cohorts are
shown in Table II.
In women there was a consistent trend towards an increased
risk of knee OA in those bearing the rs1062033 GG genotype. The
global OR was 1.28 (95% CI 1.04e1.57; P¼ 0.020) and the combined
ManteleHaenszel OR was 1.32 (95% CI 1.06e1.63; P¼ 0.011),
without evidence of heterogeneity between the three study pop-
ulations (P¼ 0.41). On the other hand, women with the CC geno-
type at rs2234693 had a lower risk of knee OA, with a global OR of
0.76 (0.59e0.97; P¼ 0.028) and combined ManteleHaenszel OR of
0.80 (0.62e1.02; P¼ 0.08), without evidence of heterogeneity
(P¼ 0.9) (Fig. 1). Both SNPs were independently associated with the
risk of knee OA, and there was no signiﬁcant interaction between
them. In the male subgroup, there were no signiﬁcant associations
between knee OA and either SNP (not shown).
Similarly, the GG genotype at rs1062033 was associated with
a nonsigniﬁcant trend for increased risk of hip OA in women (OR
1.12, 95% CI 0.95e1.33, P¼ 0.18; ManteleHaenszel OR 1.18, 95% CI
0.98e1.41, P¼ 0.075), with relatively wide between-study differ-
ences (heterogeneity P-value¼ 0.08; proportion of between-study
variance to total variance I2¼ 0.5) (Fig. 2). As for knee OA, there was
a consistent trend for lower risk of hip OA inwomen bearing the CC
genotype at rs2234693, with a global OR of 0.84, almost reaching
the conventional threshold for statistical signiﬁcance (95% CI
0.69e1.02, P¼ 0.07; ManteleHaenszel OR 0.86, 95% CI 0.70e1.06,1 426. 8.
OR
Hip OA, CYP19A1 genotype
All
Oxford
Santiago
Santander
Coruña
Fig. 3. Association of CYP19A1 SNP rs1062033 GG genotype and ESR1 SNP rs2234693 CC gen
are shown.P¼ 0.16; heterogeneity P-value 0.8). In the male subgroup
rs1062033 was not associated with hip OA. However, unlike
women, men with the CC genotype at rs2234693 had a higher risk
of hip OA, with a global OR of 1.28 (1.02e1.59; P¼ 0.029;
ManteleHaenszel OR 1.25; 95% CI 1.00e1.57, P¼ 0.048; heteroge-
neity P-value 0.9) (Fig. 3).
As shown in Table III, when the genotypes at both loci were
combined, in women the gradient risk was somewhat higher than
with any individual genotype, particularly for knee OA, with ORs
between 1.24 and 1.61 for knee OA. In men the combined analysis
did not generate more signiﬁcant data than when the SNPs were
analyzed individually (not shown).
CYP19A1 and ESR1 expression
Gene transcription of CYP19A1 and ESR1 was studied in bone
samples of 49 patients undergoing hip arthroplasty (29 men, 20
women) and the results were analyzed according to the donor’s
genotype. rs1062033 was associated with differences in the abun-
dance of CYP19A1 transcripts, which were more abundant in
samples from individuals bearing C alleles than in those bearing G
alleles (upper panel, Table IV). Intriguingly, signiﬁcant differences
in CYP19A1 transcript abundance between individuals with
different genotypes of rs2234693 were also observed (lower panel,
Table IV). However, neither the rs2234693 genotypes nor the
rs1062033 genotypes were associated with differences in the
amount of ESR1 transcripts in the bone samples (Table V).
Discussion
Estrogens are critical in the acquisition andmaintenance of bone
mass, in women as well as in men28,29, and estrogen deﬁciency
plays a major role in involutional osteoporosis. The possible role of
estrogens in OA is less well established. However, several1 426. 8.
OR
Hip OA, ESR1 genotype
Coruña
All
Oxford
Santiago
Santander
otype with hip OA in men. The individual ORs, the global combined OR and the 95% CIs
Table III
Combined analysis of rs1062033 and rs2234693 genotypes in women
rs1062033
rs2234693
No-GG
CC
No-GG
No-CC
GG
CC
GG
No-CC
P-value P-value for trend
Controls (n) 193 670 77 293
Knee OA (n) 77 350 38 188
OR 1 1.31 (0.97e1.75) 1.24 (0.77e1.98) 1.61 (1.16e2.22) 0.031 0.006
Hip OA (n) 156 717 90 330
OR 1 1.32 (1.05e1.68) 1.45 (1.00e2.09) 1.39 (1.07e1.81) 0.063 0.051
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deﬁciency may favour the development of this disease30. For
instance, Sowers et al found an inverse relationship between serum
levels of estradiol and the incidence of knee OA, even after
adjustment for age and BMI14, but others did not conﬁrm these
results31. Likewise, conﬂicting results have been published
regarding the possible preventive effect of hormone replacement
therapy on OA32,15.
Such conﬂicting results are not totally unexpected, as the local
synthesis of estrogens in bone may have important effects in
nearby tissue that are not captured by measuring circulating serum
estradiol, whilst a single point measurement may not reﬂect
adequately the overall exposure of skeletal cells to estrogens during
the lifetime period. In this regard, it has been suggested that studies
of genetic variants modulating the synthesis or activity of biological
factors may bemore informative than singlemeasurements or even
short interventional studies, as they originate the so-called
“Mendelian randomization”33,34. In this multicenter study we
found that two common polymorphisms related to the estrogen
pathway are associated with the risk of OA. Thus, women bearing
a particular genotype at the aromatase-coding gene CYP19A1 are at
an increased risk for knee OA. The effect size was relatively small
and not signiﬁcant in individual cohorts, but it was consistent and
statistically signiﬁcant in the global analysis, with an OR greater
than 1.2. The risk genotype was common, being present in about
one third of the individuals genotyped. Therefore, it may have
important consequences not only at the individual level, but also at
the population level. This risk genotype was associated with
reduced CYP19A1 expression in bone samples from patients
with OA, thus conﬁrming previous results obtained in patients with
fractures35,24. We do not have data on estrogen levels, but we
speculate that individuals with genotypes associated with reduced
CYP19A1 expression may have lower levels of aromatase and have
therefore had a lower cumulative exposure to estrogens during
their life. This would be consistent with the hypothesis that
a relative estrogen deﬁciency, either local or systemic, may favour
the development of OA13,36, and with a recent report of reduced
aromatase expression in OA22.
Aromatase is responsible for the synthesis of estrogens in post-
menopausal women and in men37. Its important role is emphasized
bystudies showingamarkeddecline inbonemass following therapy
with aromatase inhibitors38. On the other hand, type 1 estrogen
receptors (ERa) are regarded as the main receptors transducing theTable IV
CYP19A1 gene expression according to CYP19A1 and ESR1 genotypes. Values are
means SEM (arbitrary units) and 95% CIs in parentheses
CYP19A1 genotype
CC (n¼ 8) CG (n¼ 21) GG (n¼ 21) P-value
23.6 8.3 (7.3e39.9) 15.5 3.4 (8.7e22.3) 11.4 2.9 (5.8e17.0) 0.036
ESR1 genotype
TT (n¼ 14) TC (n¼ 28) GG (n¼ 7) P-value
8.4 2.4 (3.7e13.1) 16.7 3.1 (10.6e22.8) 23.6 9.2 (5.6e41.6) 0.011effect of estrogens on target cells. Based on previous results23,35,39,
we hypothesized that genetic variations of ER could also modulate
the risk of OA. In fact, although to our knowledge the association of
aromatase gene polymorphisms with OA has not been reported
previously, several investigators have explored the relationship
between ESR1 genetic variants and OA25e27,40,41. In common with
several of these studies, we found that the ESR1 SNP rs2234693 was
also associatedwith the risk ofOA inwomen, particularlyat the knee
(results for hip OA did not reach the conventional 0.05 statistical
signiﬁcance threshold) and with hip OA in men. The polymorphism
is located in intron 1 andwe speculated that it might inﬂuence gene
transcription. However, we found no signiﬁcant differences in the
abundance of ESR1 transcripts across the three ESR1 genotypes.
Interestingly, ESR1 genotypes were associated with statistically
signiﬁcant differences in CYP19A1 transcript abundance. There is no
clear explanation for this result and it obviously merits further
genetic and functional investigation; a relevant observation from
other studies is that ER may have ligand-independent and ligand-
dependent effects on the expression of genes including CYP19A142,
suggesting a trans-interaction between these two genes located in
different chromosomes. Whatever the explanation might be, our
results suggest that the alleles associated with lower aromatase
levels are associatedwith an increased risk of OA. They do not prove
a direct causal link between the genotypes and OA, but suggest that
genotype-dependent differences in estrogen levels or action inﬂu-
ence OA risk.
Although aromatase is critical for estrogen synthesis in both
postmenopausal women and men, we observed an interaction
between sex and the genotypes. Thus, whereas both rs1062033 and
rs2234693 genotypes were associated with knee OA in women, in
men rs1062033 genotypes were not associated with either hip or
knee OA, and rs2234693 genotypes were associated with hip OA,
but in an opposite direction to that observed in women. The exact
mechanisms explaining the sex-related differences are unclear.
They may be the consequence of differences in the relative
importance of acquired factors (such as physical activity) in men
and women, or reﬂect some sex-speciﬁc responses to changes in
estrogen levels, similar to what is observed in aromatase knock-out
mice and in experimental models of OA43,44.
This multicenter study included a large number of individuals,
which allowed us to increase the precision of the estimates of the
genetic effects. However, it had several limitations. First, we did not
systematically obtain X-rays of the control subjects. Therefore,Table V
ESR1 gene expression according to CYP19A1 and ESR1 genotypes (data on 37
subjects). Values are means SEM (arbitrary units) and 95% CIs in parentheses
CYP19A1 genotype
CC (n¼ 4) CG (n¼ 16) GG (n¼ 17) P-value
4.5 1.5 (1.6e7.4) 13.2 6.2 (1.1e25.3) 5.1 1.4 (2.3e7.9) 0.22
ESR1 genotype
TT (n¼ 13) TC (n¼ 18) GG (n¼ 6) P-value
5.9 1.7 (2.6e9.2) 11.8 5.6 (0.9e22.7) 4.4 2.1 (2.7e6.1) 0.90
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the results towards the null effect. On the other hand, although we
excluded cases with secondary OA, we had limited information
about anthropometric, nutritional and other environmental factors
that may inﬂuence the risk of OA. Therefore, we could not explore
possible interactions between genetic and acquired factors that can
be important in OA.
In conclusion, in this multicenter study we have shown that
common genetic variation of the aromatase gene CYP19A1 and the
ER gene ESR1, which are associated with gene expression, are also
associated with the risk of severe OA of the large joints of the lower
limb. The sex-stratiﬁed analysis suggested that the inﬂuence of the
CYP19A1 SNP is more important inwomen than inmen, and in knee
OA than in hip OA. On the other hand, the ESR1 SNPmay have a sex-
speciﬁc inﬂuence on OA risk. Overall, these results are consistent
with the hypothesis that estrogen activity may inﬂuence the
development of large-joint OA.
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